메뉴 건너뛰기




Volumn 29, Issue 4, 2015, Pages 224-230

Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; RAPAMYCIN; TACROLIMUS; BIOLOGICAL MARKER;

EID: 84960410969     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2015.04.007     Document Type: Review
Times cited : (33)

References (104)
  • 1
    • 60149110364 scopus 로고    scopus 로고
    • USRDS 2013 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States
    • National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
    • USRDS 2013 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. U.S. Renal Data System 2013, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
    • (2013) U.S. Renal Data System
  • 2
    • 79959929236 scopus 로고    scopus 로고
    • Counselling the elderly between hope and reality
    • De Fijter J.W. Counselling the elderly between hope and reality. Nephrol Dial Transplant 2011, 26:2079-2081.
    • (2011) Nephrol Dial Transplant , vol.26 , pp. 2079-2081
    • De Fijter, J.W.1
  • 3
    • 80053333600 scopus 로고    scopus 로고
    • Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes
    • Tonelli M., Wiebe N., Knoll G., et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011, 11:2093-2109.
    • (2011) Am J Transplant , vol.11 , pp. 2093-2109
    • Tonelli, M.1    Wiebe, N.2    Knoll, G.3
  • 5
    • 84960397450 scopus 로고    scopus 로고
    • ANZOD Registry Report 2013
    • ANZDATA Registry and ANZOD Registry, Adelaide
    • Excell L.M.V., Russ G. ANZOD Registry Report 2013. ANZOD Registry Report 2013, ANZDATA Registry and ANZOD Registry, Adelaide.
    • (2013) ANZOD Registry Report
    • Excell, L.M.V.1    Russ, G.2
  • 6
    • 84884537075 scopus 로고    scopus 로고
    • Donation from old living donors: how safe is it?
    • Hourmant M., Lerat L., Karam G. Donation from old living donors: how safe is it?. Nephrol Dial Transplant 2013, 28:2010-2014.
    • (2013) Nephrol Dial Transplant , vol.28 , pp. 2010-2014
    • Hourmant, M.1    Lerat, L.2    Karam, G.3
  • 7
    • 78650262647 scopus 로고    scopus 로고
    • Intermediate-term outcomes associated with kidney transplantation in recipients 80 years and older: an analysis of the OPTN/UNOS database
    • Huang E., Poommipanit N., Sampaio M.S., et al. Intermediate-term outcomes associated with kidney transplantation in recipients 80 years and older: an analysis of the OPTN/UNOS database. Transplantation 2010, 90:974-979.
    • (2010) Transplantation , vol.90 , pp. 974-979
    • Huang, E.1    Poommipanit, N.2    Sampaio, M.S.3
  • 8
    • 67649644196 scopus 로고    scopus 로고
    • Evaluating options for utility-based kidney allocation
    • Segev D.L. Evaluating options for utility-based kidney allocation. Am J Transplant 2009, 9:1513-1518.
    • (2009) Am J Transplant , vol.9 , pp. 1513-1518
    • Segev, D.L.1
  • 9
    • 59249098683 scopus 로고    scopus 로고
    • An old virtue to improve senior programs
    • De Fijter J.W. An old virtue to improve senior programs. Transpl Int 2009, 22:259-268.
    • (2009) Transpl Int , vol.22 , pp. 259-268
    • De Fijter, J.W.1
  • 10
    • 57749173132 scopus 로고    scopus 로고
    • The effects of polypharmacy in older adults
    • Hilmer S.N., Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009, 85:86-88.
    • (2009) Clin Pharmacol Ther , vol.85 , pp. 86-88
    • Hilmer, S.N.1    Gnjidic, D.2
  • 11
    • 12744278083 scopus 로고    scopus 로고
    • Age and immune response in organ transplantation
    • Martins P.N., Pratschke J., Pascher A., et al. Age and immune response in organ transplantation. Transplantation 2005, 79:127-132.
    • (2005) Transplantation , vol.79 , pp. 127-132
    • Martins, P.N.1    Pratschke, J.2    Pascher, A.3
  • 13
    • 84867097855 scopus 로고    scopus 로고
    • Solid-organ transplantation in older adults: current status and future research
    • Abecassis M., Bridges N.D., Clancy C.J., et al. Solid-organ transplantation in older adults: current status and future research. Am J Transplant 2012, 12:2608-2622.
    • (2012) Am J Transplant , vol.12 , pp. 2608-2622
    • Abecassis, M.1    Bridges, N.D.2    Clancy, C.J.3
  • 14
    • 21044451726 scopus 로고    scopus 로고
    • The influence of age on T cell generation and TCR diversity
    • Naylor K., Li G., Vallejo A.N., et al. The influence of age on T cell generation and TCR diversity. J Immunol 2005, 174:7446-7452.
    • (2005) J Immunol , vol.174 , pp. 7446-7452
    • Naylor, K.1    Li, G.2    Vallejo, A.N.3
  • 15
    • 40849145398 scopus 로고    scopus 로고
    • T cell subset-specific susceptibility to aging
    • Czesnikiewicz-Guzik M., Lee W.W., Cui D., et al. T cell subset-specific susceptibility to aging. Clin Immunol 2008, 127:107-118.
    • (2008) Clin Immunol , vol.127 , pp. 107-118
    • Czesnikiewicz-Guzik, M.1    Lee, W.W.2    Cui, D.3
  • 16
    • 84855961969 scopus 로고    scopus 로고
    • Advances in direct T-cell alloreactivity: function, avidity, biophysics and structure
    • Smith C., Miles J.J., Khanna R. Advances in direct T-cell alloreactivity: function, avidity, biophysics and structure. Am J Transplant 2012, 12:15-26.
    • (2012) Am J Transplant , vol.12 , pp. 15-26
    • Smith, C.1    Miles, J.J.2    Khanna, R.3
  • 17
    • 77949495502 scopus 로고    scopus 로고
    • Prolonged graft survival in older recipient mice is determined by impaired effector T-cell but intact regulatory T-cell responses
    • Denecke C., Bedi D.S., Ge X., et al. Prolonged graft survival in older recipient mice is determined by impaired effector T-cell but intact regulatory T-cell responses. PLoS One 2010, 5:e9232.
    • (2010) PLoS One , vol.5 , pp. e9232
    • Denecke, C.1    Bedi, D.S.2    Ge, X.3
  • 18
    • 78650899002 scopus 로고    scopus 로고
    • Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression
    • Lo D.J., Weaver T.A., Stempora L., et al. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant 2011, 11:22-33.
    • (2011) Am J Transplant , vol.11 , pp. 22-33
    • Lo, D.J.1    Weaver, T.A.2    Stempora, L.3
  • 19
    • 0034653643 scopus 로고    scopus 로고
    • Increased immunosuppressive vulnerability in elderly renal transplant recipients
    • Meier-Kriesche H.U., Ojo A., Hanson J., et al. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 2000, 69:885-889.
    • (2000) Transplantation , vol.69 , pp. 885-889
    • Meier-Kriesche, H.U.1    Ojo, A.2    Hanson, J.3
  • 20
    • 58249108425 scopus 로고    scopus 로고
    • The OPTN/UNOS renal transplant registry
    • Cecka J.M. The OPTN/UNOS renal transplant registry. Clin Transpl 2004, 1-16.
    • (2004) Clin Transpl , pp. 1-16
    • Cecka, J.M.1
  • 21
    • 12444346875 scopus 로고    scopus 로고
    • Renal transplant recipients over aged 60 have diminished immune activity and a low risk of rejection
    • Friedman A.L., Goker O., Kalish M.A., et al. Renal transplant recipients over aged 60 have diminished immune activity and a low risk of rejection. Int Urol Nephrol 2004, 36:451-456.
    • (2004) Int Urol Nephrol , vol.36 , pp. 451-456
    • Friedman, A.L.1    Goker, O.2    Kalish, M.A.3
  • 23
    • 79953798838 scopus 로고    scopus 로고
    • Kidney allocation and the aging immune response
    • Tullius S.G., Milford E. Kidney allocation and the aging immune response. N Engl J Med 2011, 364:1369-1370.
    • (2011) N Engl J Med , vol.364 , pp. 1369-1370
    • Tullius, S.G.1    Milford, E.2
  • 25
    • 22344433724 scopus 로고    scopus 로고
    • The impact of age on rejection in kidney transplantation
    • De Fijter J.W. The impact of age on rejection in kidney transplantation. Drugs Aging 2005, 22:433-449.
    • (2005) Drugs Aging , vol.22 , pp. 433-449
    • De Fijter, J.W.1
  • 26
    • 0034923878 scopus 로고    scopus 로고
    • Increased immunogenicity and cause of graft loss of old donor kidneys
    • De Fijter J.W., Mallat M.J., Doxiadis Ii, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001, 12:1538-1546.
    • (2001) J Am Soc Nephrol , vol.12 , pp. 1538-1546
    • De Fijter, J.W.1    Mallat, M.J.2    Doxiadis, I.3
  • 27
    • 84860473178 scopus 로고    scopus 로고
    • Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant
    • Wiebe C., Gibson I.W., Blydt-Hansen T.D., et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012, 12:1157-1167.
    • (2012) Am J Transplant , vol.12 , pp. 1157-1167
    • Wiebe, C.1    Gibson, I.W.2    Blydt-Hansen, T.D.3
  • 28
    • 0035679073 scopus 로고    scopus 로고
    • Interaction between acute rejection and recipient age on long-term renal allograft survival
    • Meier-Kriesche H.U., Srinivas T.R., Kaplan B. Interaction between acute rejection and recipient age on long-term renal allograft survival. Transplant Proc 2001, 33:3425-3426.
    • (2001) Transplant Proc , vol.33 , pp. 3425-3426
    • Meier-Kriesche, H.U.1    Srinivas, T.R.2    Kaplan, B.3
  • 29
    • 0343628707 scopus 로고    scopus 로고
    • Relationship of recipient age and development of chronic allograft failure
    • Meier-Kriesche H.U., Ojo A.O., Cibrik D.M., et al. Relationship of recipient age and development of chronic allograft failure. Transplantation 2000, 70:306-310.
    • (2000) Transplantation , vol.70 , pp. 306-310
    • Meier-Kriesche, H.U.1    Ojo, A.O.2    Cibrik, D.M.3
  • 30
    • 84876297635 scopus 로고    scopus 로고
    • Kidney transplantation in the older adult
    • Knoll G.A. Kidney transplantation in the older adult. Am J Kidney Dis 2013, 61:790-797.
    • (2013) Am J Kidney Dis , vol.61 , pp. 790-797
    • Knoll, G.A.1
  • 31
    • 34547876470 scopus 로고    scopus 로고
    • Immunosuppression of the elderly kidney transplant recipient
    • Danovitch G.M., Gill J., Bunnapradist S. Immunosuppression of the elderly kidney transplant recipient. Transplantation 2007, 84:285-291.
    • (2007) Transplantation , vol.84 , pp. 285-291
    • Danovitch, G.M.1    Gill, J.2    Bunnapradist, S.3
  • 32
    • 0035070003 scopus 로고    scopus 로고
    • Exponentially increased risk of infectious death in older renal transplant recipients
    • Meier-Kriesche H.U., Ojo A.O., Hanson J.A., Kaplan B. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int 2001, 59:1539-1543.
    • (2001) Kidney Int , vol.59 , pp. 1539-1543
    • Meier-Kriesche, H.U.1    Ojo, A.O.2    Hanson, J.A.3    Kaplan, B.4
  • 33
    • 27644454209 scopus 로고    scopus 로고
    • Influence of age in renal transplant infections: cases and controls study
    • Trouillhet I., Benito N., Cervera C., et al. Influence of age in renal transplant infections: cases and controls study. Transplantation 2005, 80:989-992.
    • (2005) Transplantation , vol.80 , pp. 989-992
    • Trouillhet, I.1    Benito, N.2    Cervera, C.3
  • 34
    • 79953812140 scopus 로고    scopus 로고
    • Renal transplantation in the elderly: South Indian experience
    • Mohamed Ali A.A., Abraham G., Khanna P., et al. Renal transplantation in the elderly: South Indian experience. Int Urol Nephrol 2011, 43:265-271.
    • (2011) Int Urol Nephrol , vol.43 , pp. 265-271
    • Mohamed Ali, A.A.1    Abraham, G.2    Khanna, P.3
  • 35
    • 55749114725 scopus 로고    scopus 로고
    • What is the best immunosuppression for the elderly kidney transplantation patient?
    • Ladriere M. What is the best immunosuppression for the elderly kidney transplantation patient?. Nephrol Ther 2008, 4:S179-S183.
    • (2008) Nephrol Ther , vol.4 , pp. S179-S183
    • Ladriere, M.1
  • 36
    • 84879514567 scopus 로고    scopus 로고
    • Managing transplant rejection in the elderly: the benefits of less aggressive immunosuppressive regimens
    • Heldal K., Midtvedt K. Managing transplant rejection in the elderly: the benefits of less aggressive immunosuppressive regimens. Drugs Aging 2013, 30:459-466.
    • (2013) Drugs Aging , vol.30 , pp. 459-466
    • Heldal, K.1    Midtvedt, K.2
  • 37
    • 9644299890 scopus 로고    scopus 로고
    • Drug therapy in the elderly
    • Turnheim K. Drug therapy in the elderly. Exp Gerontol 2004, 39:1731-1738.
    • (2004) Exp Gerontol , vol.39 , pp. 1731-1738
    • Turnheim, K.1
  • 38
    • 39149117687 scopus 로고    scopus 로고
    • The clinical implications of ageing for rational drug therapy
    • Shi S., Morike K., Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008, 64:183-199.
    • (2008) Eur J Clin Pharmacol , vol.64 , pp. 183-199
    • Shi, S.1    Morike, K.2    Klotz, U.3
  • 39
    • 0347319044 scopus 로고    scopus 로고
    • Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications
    • Mangoni A.A., Jackson S.H. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004, 57:6-14.
    • (2004) Br J Clin Pharmacol , vol.57 , pp. 6-14
    • Mangoni, A.A.1    Jackson, S.H.2
  • 40
    • 0035214978 scopus 로고    scopus 로고
    • Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive?
    • Meier-Kriesche H.U., Kaplan B. Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive?. Drugs Aging 2001, 18:751-759.
    • (2001) Drugs Aging , vol.18 , pp. 751-759
    • Meier-Kriesche, H.U.1    Kaplan, B.2
  • 41
    • 1942435960 scopus 로고    scopus 로고
    • Drug therapy in transplant recipients: special considerations in the elderly with comorbid conditions
    • Bernardo J.F., Mccauley J. Drug therapy in transplant recipients: special considerations in the elderly with comorbid conditions. Drugs Aging 2004, 21:323-348.
    • (2004) Drugs Aging , vol.21 , pp. 323-348
    • Bernardo, J.F.1    Mccauley, J.2
  • 43
    • 12644272784 scopus 로고    scopus 로고
    • Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
    • Lown K.S., Mayo R.R., Leichtman A.B., et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997, 62:248-260.
    • (1997) Clin Pharmacol Ther , vol.62 , pp. 248-260
    • Lown, K.S.1    Mayo, R.R.2    Leichtman, A.B.3
  • 44
    • 34548695887 scopus 로고    scopus 로고
    • Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum
    • Canaparo R., Finnstrom N., Serpe L., et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007, 34:1138-1144.
    • (2007) Clin Exp Pharmacol Physiol , vol.34 , pp. 1138-1144
    • Canaparo, R.1    Finnstrom, N.2    Serpe, L.3
  • 45
    • 31344466713 scopus 로고    scopus 로고
    • Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients
    • Uesugi M., Masuda S., Katsura T., Oike F., Takada Y., Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006, 16:119-127.
    • (2006) Pharmacogenet Genomics , vol.16 , pp. 119-127
    • Uesugi, M.1    Masuda, S.2    Katsura, T.3    Oike, F.4    Takada, Y.5    Inui, K.6
  • 46
    • 42149176588 scopus 로고    scopus 로고
    • Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients
    • Fukudo M., Yano I., Yoshimura A., et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008, 18:413-423.
    • (2008) Pharmacogenet Genomics , vol.18 , pp. 413-423
    • Fukudo, M.1    Yano, I.2    Yoshimura, A.3
  • 47
    • 0036231685 scopus 로고    scopus 로고
    • The aging liver: structural and functional changes and their consequences for drug treatment in old age
    • Zeeh J., Platt D. The aging liver: structural and functional changes and their consequences for drug treatment in old age. Gerontology 2002, 48:121-127.
    • (2002) Gerontology , vol.48 , pp. 121-127
    • Zeeh, J.1    Platt, D.2
  • 48
    • 11944274532 scopus 로고    scopus 로고
    • The influence of age and sex on the clearance of cytochrome P450 3A substrates
    • Cotreau M.M., Von Moltke L.L., Greenblatt D.J. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005, 44:33-60.
    • (2005) Clin Pharmacokinet , vol.44 , pp. 33-60
    • Cotreau, M.M.1    Von Moltke, L.L.2    Greenblatt, D.J.3
  • 49
    • 25844458497 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals
    • Ginsberg G., Hattis D., Russ A., Sonawane B. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ Health Perspect 2005, 113:1243-1249.
    • (2005) Environ Health Perspect , vol.113 , pp. 1243-1249
    • Ginsberg, G.1    Hattis, D.2    Russ, A.3    Sonawane, B.4
  • 50
    • 33646165075 scopus 로고    scopus 로고
    • Erythromycin breath test results in elderly, very elderly, and frail elderly persons
    • Schwartz J.B. Erythromycin breath test results in elderly, very elderly, and frail elderly persons. Clin Pharmacol Ther 2006, 79:440-448.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 440-448
    • Schwartz, J.B.1
  • 51
    • 0042707810 scopus 로고    scopus 로고
    • When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly
    • Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003, 38:843-853.
    • (2003) Exp Gerontol , vol.38 , pp. 843-853
    • Turnheim, K.1
  • 52
    • 46049118014 scopus 로고    scopus 로고
    • Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity
    • Dimartini A., Fontes P., Dew M.A., Lotrich F.E., De Vera M. Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity. Liver Transpl 2008, 14:815-822.
    • (2008) Liver Transpl , vol.14 , pp. 815-822
    • Dimartini, A.1    Fontes, P.2    Dew, M.A.3    Lotrich, F.E.4    De Vera, M.5
  • 54
    • 24644438250 scopus 로고    scopus 로고
    • Age-related changes in liver structure and function: implications for disease?
    • Schmucker D.L. Age-related changes in liver structure and function: implications for disease?. Exp Gerontol 2005, 40:650-659.
    • (2005) Exp Gerontol , vol.40 , pp. 650-659
    • Schmucker, D.L.1
  • 55
    • 69949163535 scopus 로고    scopus 로고
    • Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions
    • Kuypers D.R. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging 2009, 26:715-737.
    • (2009) Drugs Aging , vol.26 , pp. 715-737
    • Kuypers, D.R.1
  • 56
    • 55549129627 scopus 로고    scopus 로고
    • Pharmacodynamic parameters of immunosuppressive drugs are not correlated with age, duration of dialysis, percentage of lymphocytes or lymphocyte stimulation index in renal transplant recipients
    • Sugiyama K., Isogai K., Toyama A., et al. Pharmacodynamic parameters of immunosuppressive drugs are not correlated with age, duration of dialysis, percentage of lymphocytes or lymphocyte stimulation index in renal transplant recipients. Biol Pharm Bull 2008, 31:2146-2149.
    • (2008) Biol Pharm Bull , vol.31 , pp. 2146-2149
    • Sugiyama, K.1    Isogai, K.2    Toyama, A.3
  • 57
    • 0031727173 scopus 로고    scopus 로고
    • Drug dosage in the elderly. Is it rational?
    • Turnheim K. Drug dosage in the elderly. Is it rational?. Drugs Aging 1998, 13:357-379.
    • (1998) Drugs Aging , vol.13 , pp. 357-379
    • Turnheim, K.1
  • 58
    • 24044443235 scopus 로고    scopus 로고
    • Pharmacokinetic considerations relating to tacrolimus dosing in the elderly
    • Staatz C.E., Tett S.E. Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. Drugs Aging 2005, 22:541-557.
    • (2005) Drugs Aging , vol.22 , pp. 541-557
    • Staatz, C.E.1    Tett, S.E.2
  • 59
    • 84893233177 scopus 로고    scopus 로고
    • The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation
    • Hesselink D.A., Bouamar R., Elens L., Van Schaik R.H., Van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet 2014, 53:123-139.
    • (2014) Clin Pharmacokinet , vol.53 , pp. 123-139
    • Hesselink, D.A.1    Bouamar, R.2    Elens, L.3    Van Schaik, R.H.4    Van Gelder, T.5
  • 60
    • 34447549311 scopus 로고    scopus 로고
    • Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms
    • Op Den Buijsch R.A., Christiaans M.H., Stolk L.M., et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007, 21:427-435.
    • (2007) Fundam Clin Pharmacol , vol.21 , pp. 427-435
    • Op Den Buijsch, R.A.1    Christiaans, M.H.2    Stolk, L.M.3
  • 61
    • 3242772986 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
    • Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004, 43:623-653.
    • (2004) Clin Pharmacokinet , vol.43 , pp. 623-653
    • Staatz, C.E.1    Tett, S.E.2
  • 62
    • 33646439263 scopus 로고    scopus 로고
    • Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients
    • Wei-Lin W., Jing J., Shu-Sen Z., et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006, 12:775-780.
    • (2006) Liver Transpl , vol.12 , pp. 775-780
    • Wei-Lin, W.1    Jing, J.2    Shu-Sen, Z.3
  • 63
    • 70349243452 scopus 로고    scopus 로고
    • No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation
    • Miura M., Satoh S., Kagaya H., et al. No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. Eur J Clin Pharmacol 2009, 65:1047-1053.
    • (2009) Eur J Clin Pharmacol , vol.65 , pp. 1047-1053
    • Miura, M.1    Satoh, S.2    Kagaya, H.3
  • 65
    • 84870507915 scopus 로고    scopus 로고
    • Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs
    • Jacobson P.A., Schladt D., Oetting W.S., et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant 2012, 12:3326-3336.
    • (2012) Am J Transplant , vol.12 , pp. 3326-3336
    • Jacobson, P.A.1    Schladt, D.2    Oetting, W.S.3
  • 66
    • 84888013795 scopus 로고    scopus 로고
    • Population pharmacokinetics of cyclosporine in transplant recipients
    • Han K., Pillai V.C., Venkataramanan R. Population pharmacokinetics of cyclosporine in transplant recipients. AAPS J 2013, 15:901-912.
    • (2013) AAPS J , vol.15 , pp. 901-912
    • Han, K.1    Pillai, V.C.2    Venkataramanan, R.3
  • 67
    • 69849104464 scopus 로고    scopus 로고
    • A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients
    • Falck P., Midtvedt K., Van Le T.T., et al. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. Clin Pharmacokinet 2009, 48:615-623.
    • (2009) Clin Pharmacokinet , vol.48 , pp. 615-623
    • Falck, P.1    Midtvedt, K.2    Van Le, T.T.3
  • 68
    • 23944478373 scopus 로고    scopus 로고
    • Population pharmacokinetics of cyclosporine in clinical renal transplant patients
    • Wu K.H., Cui Y.M., Guo J.F., et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos 2005, 33:1268-1275.
    • (2005) Drug Metab Dispos , vol.33 , pp. 1268-1275
    • Wu, K.H.1    Cui, Y.M.2    Guo, J.F.3
  • 69
    • 0032837161 scopus 로고    scopus 로고
    • Cyclosporin pharmacokinetics in the elderly
    • Kovarik J.M., Koelle E.U. Cyclosporin pharmacokinetics in the elderly. Drugs Aging 1999, 15:197-205.
    • (1999) Drugs Aging , vol.15 , pp. 197-205
    • Kovarik, J.M.1    Koelle, E.U.2
  • 70
    • 58149354277 scopus 로고    scopus 로고
    • Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients
    • Falck P., Asberg A., Byberg K.T., et al. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. Transplantation 2008, 86:1379-1383.
    • (2008) Transplantation , vol.86 , pp. 1379-1383
    • Falck, P.1    Asberg, A.2    Byberg, K.T.3
  • 71
    • 84903439322 scopus 로고    scopus 로고
    • Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update
    • Staatz C.E., Tett S.E. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol 2014, 88:1351-1389.
    • (2014) Arch Toxicol , vol.88 , pp. 1351-1389
    • Staatz, C.E.1    Tett, S.E.2
  • 72
    • 0038246498 scopus 로고    scopus 로고
    • Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies
    • Shaw L.M., Korecka M., Venkataramanan R., Goldberg L., Bloom R., Brayman K.L. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003, 3:534-542.
    • (2003) Am J Transplant , vol.3 , pp. 534-542
    • Shaw, L.M.1    Korecka, M.2    Venkataramanan, R.3    Goldberg, L.4    Bloom, R.5    Brayman, K.L.6
  • 73
    • 0033160692 scopus 로고    scopus 로고
    • The effect of renal insufficiency on mycophenolic acid protein binding
    • Kaplan B., Meier-Kriesche H.U., Friedman G., et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999, 39:715-720.
    • (1999) J Clin Pharmacol , vol.39 , pp. 715-720
    • Kaplan, B.1    Meier-Kriesche, H.U.2    Friedman, G.3
  • 74
    • 33645450634 scopus 로고    scopus 로고
    • Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients
    • Van Hest R.M., Mathot R.A., Pescovitz M.D., Gordon R., Mamelok R.D., Van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006, 17:871-880.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 871-880
    • Van Hest, R.M.1    Mathot, R.A.2    Pescovitz, M.D.3    Gordon, R.4    Mamelok, R.D.5    Van Gelder, T.6
  • 75
    • 34250204444 scopus 로고    scopus 로고
    • Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients
    • Wang C.X., Meng F.H., Chen L.Z., et al. Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients. Transplant Proc 2007, 39:1392-1395.
    • (2007) Transplant Proc , vol.39 , pp. 1392-1395
    • Wang, C.X.1    Meng, F.H.2    Chen, L.Z.3
  • 76
    • 0034746371 scopus 로고    scopus 로고
    • Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine
    • Kovarik J.M., Kahan B.D., Kaplan B., et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001, 69:48-56.
    • (2001) Clin Pharmacol Ther , vol.69 , pp. 48-56
    • Kovarik, J.M.1    Kahan, B.D.2    Kaplan, B.3
  • 77
    • 0034834765 scopus 로고    scopus 로고
    • Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications
    • Kovarik J.M., Hsu C.H., Mcmahon L., Berthier S., Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001, 70:247-254.
    • (2001) Clin Pharmacol Ther , vol.70 , pp. 247-254
    • Kovarik, J.M.1    Hsu, C.H.2    Mcmahon, L.3    Berthier, S.4    Rordorf, C.5
  • 78
    • 84903786099 scopus 로고    scopus 로고
    • Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes
    • Shihab F., Christians U., Smith L., Wellen J.R., Kaplan B. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol 2014, 31:22-32.
    • (2014) Transpl Immunol , vol.31 , pp. 22-32
    • Shihab, F.1    Christians, U.2    Smith, L.3    Wellen, J.R.4    Kaplan, B.5
  • 80
    • 33748750319 scopus 로고    scopus 로고
    • A Bayesian approach for population pharmacokinetic modelling of sirolimus
    • Dansirikul C., Morris R.G., Tett S.E., Duffull S.B. A Bayesian approach for population pharmacokinetic modelling of sirolimus. Br J Clin Pharmacol 2006, 62:420-434.
    • (2006) Br J Clin Pharmacol , vol.62 , pp. 420-434
    • Dansirikul, C.1    Morris, R.G.2    Tett, S.E.3    Duffull, S.B.4
  • 81
    • 84864127871 scopus 로고    scopus 로고
    • Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients
    • Zhou Z., Shen J., Hong Y., Kaul S., Pfister M., Roy A. Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther 2012, 92:251-257.
    • (2012) Clin Pharmacol Ther , vol.92 , pp. 251-257
    • Zhou, Z.1    Shen, J.2    Hong, Y.3    Kaul, S.4    Pfister, M.5    Roy, A.6
  • 82
    • 76949101581 scopus 로고    scopus 로고
    • A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)
    • Vincenti F., Charpentier B., Vanrenterghem Y., et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10:535-546.
    • (2010) Am J Transplant , vol.10 , pp. 535-546
    • Vincenti, F.1    Charpentier, B.2    Vanrenterghem, Y.3
  • 83
    • 76949090842 scopus 로고    scopus 로고
    • A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)
    • Durrbach A., Pestana J.M., Pearson T., et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010, 10:547-557.
    • (2010) Am J Transplant , vol.10 , pp. 547-557
    • Durrbach, A.1    Pestana, J.M.2    Pearson, T.3
  • 84
    • 84876289552 scopus 로고    scopus 로고
    • FDA perspective: enrolment of elderly transplant recipients in clinical trials
    • Meyer J.M., Archdeacon P., Albrecht R. FDA perspective: enrolment of elderly transplant recipients in clinical trials. Transplantation 2013, 95:916-918.
    • (2013) Transplantation , vol.95 , pp. 916-918
    • Meyer, J.M.1    Archdeacon, P.2    Albrecht, R.3
  • 85
    • 75649088107 scopus 로고    scopus 로고
    • Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives
    • Van Rossum H.H., De Fijter J.W., Van Pelt J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther Drug Monit 2010, 32:3-10.
    • (2010) Ther Drug Monit , vol.32 , pp. 3-10
    • Van Rossum, H.H.1    De Fijter, J.W.2    Van Pelt, J.3
  • 86
    • 34548687467 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic
    • Brunet M., Crespo M., Millan O., et al. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. Transplant Proc 2007, 39:2160-2162.
    • (2007) Transplant Proc , vol.39 , pp. 2160-2162
    • Brunet, M.1    Crespo, M.2    Millan, O.3
  • 87
    • 84862759750 scopus 로고    scopus 로고
    • Calcineurin inhibitors and NFAT-regulated gene expression
    • Sommerer C., Meuer S., Zeier M., Giese T. Calcineurin inhibitors and NFAT-regulated gene expression. Clin Chim Acta 2012, 413:1379-1386.
    • (2012) Clin Chim Acta , vol.413 , pp. 1379-1386
    • Sommerer, C.1    Meuer, S.2    Zeier, M.3    Giese, T.4
  • 88
    • 80051802715 scopus 로고    scopus 로고
    • Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia
    • Sommerer C., Zeier M., Czock D., Schnitzler P., Meuer S., Giese T. Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. Ther Drug Monit 2011, 33:373-379.
    • (2011) Ther Drug Monit , vol.33 , pp. 373-379
    • Sommerer, C.1    Zeier, M.2    Czock, D.3    Schnitzler, P.4    Meuer, S.5    Giese, T.6
  • 89
    • 77953359811 scopus 로고    scopus 로고
    • Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients
    • Sommerer C., Zeier M., Meuer S., Giese T. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation 2010, 89:1417-1423.
    • (2010) Transplantation , vol.89 , pp. 1417-1423
    • Sommerer, C.1    Zeier, M.2    Meuer, S.3    Giese, T.4
  • 90
    • 84893417691 scopus 로고    scopus 로고
    • Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes-a prospective stud
    • Steinebrunner N., Sandig C., Sommerer C., et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes-a prospective stud. Ann Transplant 2014, 19:32-40.
    • (2014) Ann Transplant , vol.19 , pp. 32-40
    • Steinebrunner, N.1    Sandig, C.2    Sommerer, C.3
  • 91
    • 84856115743 scopus 로고    scopus 로고
    • Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older
    • Sommerer C., Schnitzler P., Meuer S., Zeier M., Giese T. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. Ther Drug Monit 2011, 33:694-698.
    • (2011) Ther Drug Monit , vol.33 , pp. 694-698
    • Sommerer, C.1    Schnitzler, P.2    Meuer, S.3    Zeier, M.4    Giese, T.5
  • 92
    • 34248158954 scopus 로고    scopus 로고
    • Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications
    • Weimert N.A., Derotte M., Alloway R.R., Woodle E.S., Vinks A.A. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit 2007, 29:141-149.
    • (2007) Ther Drug Monit , vol.29 , pp. 141-149
    • Weimert, N.A.1    Derotte, M.2    Alloway, R.R.3    Woodle, E.S.4    Vinks, A.A.5
  • 93
    • 84892902706 scopus 로고    scopus 로고
    • Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation
    • Saeves I., Line P.D., Bremer S., et al. Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. Ther Drug Monit 2014, 36:46-53.
    • (2014) Ther Drug Monit , vol.36 , pp. 46-53
    • Saeves, I.1    Line, P.D.2    Bremer, S.3
  • 94
    • 13144281731 scopus 로고    scopus 로고
    • Mycophenolate mofetil: how to further improve using an already successful drug?
    • Van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug?. Am J Transplant 2005, 5:199-200.
    • (2005) Am J Transplant , vol.5 , pp. 199-200
    • Van Gelder, T.1
  • 95
    • 33846230492 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients
    • Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13-58.
    • (2007) Clin Pharmacokinet , vol.46 , pp. 13-58
    • Staatz, C.E.1    Tett, S.E.2
  • 96
    • 70349668493 scopus 로고    scopus 로고
    • Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not
    • Sombogaard F., Peeters A.M., Baan C.C., et al. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit 2009, 31:549-556.
    • (2009) Ther Drug Monit , vol.31 , pp. 549-556
    • Sombogaard, F.1    Peeters, A.M.2    Baan, C.C.3
  • 97
    • 32844467779 scopus 로고    scopus 로고
    • Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy
    • Hartmann B., Schmid G., Graeb C., et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int 2005, 68:2593-2598.
    • (2005) Kidney Int , vol.68 , pp. 2593-2598
    • Hartmann, B.1    Schmid, G.2    Graeb, C.3
  • 98
    • 34447622296 scopus 로고    scopus 로고
    • Monitoring biological action of rapamycin in renal transplantation
    • Leogrande D., Teutonico A., Ranieri E., et al. Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis 2007, 50:314-325.
    • (2007) Am J Kidney Dis , vol.50 , pp. 314-325
    • Leogrande, D.1    Teutonico, A.2    Ranieri, E.3
  • 99
    • 84875185944 scopus 로고    scopus 로고
    • Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition
    • Hartmann B., He X., Keller F., Fischereder M., Guba M., Schmid H. Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition. Ther Drug Monit 2013, 35:233-239.
    • (2013) Ther Drug Monit , vol.35 , pp. 233-239
    • Hartmann, B.1    He, X.2    Keller, F.3    Fischereder, M.4    Guba, M.5    Schmid, H.6
  • 100
    • 84920271436 scopus 로고    scopus 로고
    • Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity
    • Hoerning A., Wilde B., Wang J., et al. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. Transplantation 2015, 99:210-219.
    • (2015) Transplantation , vol.99 , pp. 210-219
    • Hoerning, A.1    Wilde, B.2    Wang, J.3
  • 101
    • 75749102266 scopus 로고    scopus 로고
    • Kidney disease: improving global outcomes transplant work G. KDIGO clinical practice guideline for the care of kidney transplant recipients
    • Kidney disease: improving global outcomes transplant work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9:S1-S155.
    • (2009) Am J Transplant , vol.9 , pp. S1-S155
  • 102
    • 79957843431 scopus 로고    scopus 로고
    • Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States
    • Gill J., Sampaio M., Gill J.S., et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol 2011, 6:1168-1178.
    • (2011) Clin J Am Soc Nephrol , vol.6 , pp. 1168-1178
    • Gill, J.1    Sampaio, M.2    Gill, J.S.3
  • 103
    • 79953193081 scopus 로고    scopus 로고
    • Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy
    • Laftavi M.R., Patel S., Soliman M.R., et al. Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. Transplant Proc 2011, 43:466-468.
    • (2011) Transplant Proc , vol.43 , pp. 466-468
    • Laftavi, M.R.1    Patel, S.2    Soliman, M.R.3
  • 104
    • 84880070494 scopus 로고    scopus 로고
    • Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients
    • Khanmoradi K., Knorr J.P., Feyssa E.L., et al. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients. Exp Clin Transplant 2013, 11:222-228.
    • (2013) Exp Clin Transplant , vol.11 , pp. 222-228
    • Khanmoradi, K.1    Knorr, J.P.2    Feyssa, E.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.